674 results on '"Hoffman, Hal M."'
Search Results
202. Autoinflammation: translating mechanism to therapy
203. Correction: An Inflammasome-Independent Role for Epithelial-Expressed Nlrp3 in Renal Ischemia-Reperfusion Injury
204. Recurrent Fever Syndromes in Patients After Recovery From Kawasaki Syndrome
205. Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9–driven antiinflammatory cytokine production
206. An Inflammasome-Independent Role for Epithelial-Expressed Nlrp3 in Renal Ischemia-Reperfusion Injury
207. IL-1-3 IL-1 and the inflammasome
208. Inflammasome and IL-1β-Mediated Disorders
209. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
210. NLRP3/Cryopyrin Is Necessary for Interleukin-1β (IL-1β) Release in Response to Hyaluronan, an Endogenous Trigger of Inflammation in Response to Injury
211. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS)
212. Identification of EpCAM as the Gene for Congenital Tufting Enteropathy
213. Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity
214. Rilonacept
215. Microbial Pathogen-Induced Necrotic Cell Death Mediated by the Inflammasome Components CIAS1/Cryopyrin/NLRP3 and ASC
216. Association between celiac sprue and cryopyrin associated autoinflammatory disorders: a case report
217. Reply
218. MDP-induced interleukin-1β processing requires Nod2 and CIAS1/NALP3
219. Response to IL-1-Receptor Antagonist in a Child with Familial Cold Autoinflammatory Syndrome
220. NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms.
221. The inflammasome adaptor ASC contributes to multiple innate immune processes in the resolution of otitis media.
222. Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart.
223. Inflammasome activation leads to Caspase-1–dependent mitochondrial damage and block of mitophagy.
224. IL-Converting Enzyme/Caspase-1 Inhibitor VX-765 Blocks the Hypersensitive Response to an Inflammatory Stimulus in Monocytes from Familial Cold Autoinflammatory Syndrome Patients
225. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity
226. Reply
227. Structural, expression, and evolutionary analysis of mouse CIAS1
228. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome
229. Humoral immunodeficiency with facial dysmorphology and limb anomalies: a new syndrome
230. Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease–Associated Abdominal Aortic Aneurysm
231. IL-1 Signaling Is Critically Required in Stromal Cells in Kawasaki Disease Vasculitis Mouse Model
232. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice.
233. Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry.
234. EOSINOPHILIA IN AIDS
235. 0RMDL3 is an inducible lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6.
236. Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopryin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study
237. Genetic and Molecular Basis of lnflammasome-mediated Disease.
238. Treatment of patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome: comment on the article Matsubara et al.
239. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle?Wells syndrome.
240. Neutrophil-specific gain-of-function mutations in Nlrp3 promote development of cryopyrin-associated periodic syndrome
241. Pediatric recurrent fever and autoinflammation from the perspective of an allergist/immunologist.
242. Vitamin D ameliorates adipose browning in chronic kidney disease cachexia.
243. Author Correction: A guiding map for inflammation
244. Choline Uptake and Metabolism Modulate Macrophage IL-1β and IL-18 Production.
245. Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes
246. Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
247. Intestinal fungi contribute to development of alcoholic liver disease
248. Development and Validation of Diagnostic Criteria for Cryopyrin Associated Periodic Syndromes
249. Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial
250. Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant Familial Mediterranean Fever, Hyper-Immunoglobulin D Syndrome/Mevalonate Kinase Deficiency and TNF Receptor-Associated Periodic Syndrome: 40 Week Results from the Pivotal Phase 3 Umbrella Cluster Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.